Rise to the Challenge: Master the Management of Clostridioides difficile Infection.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38839189.
- Also identified by DOI 10.1016/j.mayocp.2024.02.022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Clostridioides difficile infection (CDI) is a significant public health challenge in the developed world. Although previously CDI was primarily a health care-acquired infection, there are now rising numbers of community-acquired cases in patients without traditional risk factors, such as antibiotic exposure. The landscape for the treatment of CDI has changed significantly during the past decade, including newer diagnostic tests, novel antibiotic regimens, and strategies for microbiome restoration in the form of traditional fecal microbiota transplant and approved live biotherapeutics in an effort to address the underlying pathophysiologic process of gut microbial dysbiosis. We present a concise review for clinicians on the diagnosis and management of both primary and recurrent CDI.
Medical subject headings
- Clostridium Infections
- Anti-Bacterial Agents
- Fecal Microbiota Transplantation